This page is the continuation of reference in support of Section 6d
REFERENCES
Abd El-Rehim, D.M., Pinder, S.E., Paish, C.E., et al. (2004). Expression of luminal and basal cytokeratins in human breast carcinoma. J Pathol. 203, 661–671. (Retrieved November 19th 2014): https://www.ncbi.nlm.nih.gov/pubmed/15141381
Acs, G., Lawton, T.J., Rebbeck, T.R., Livolsi, V.A., Zhang, P.J. (2001). Differential expression of E-cadherin in lobular and ductal neoplasms of the breast and its biologic and diagnostic implications. Am J Clin Pathol. 115, 85–98. (Retrieved November 19th 2014): https://www.ncbi.nlm.nih.gov/pubmed/11190811
Albain, K.S., Carey, L., Gradishar, W.J., et al. (2010). Proceedings of the First Global Workshop on Breast Cancer: Pathways to the evaluation and clinical development of novel agents for breast cancer. Clin. Breast Cancer 10, 421–439. (Retrieved November 19th 2014): https://www.ncbi.nlm.nih.gov/pubmed/21147685
Alizadeh, A.A., Ross, D.T., Perou, C.M., van de Rijn, M. (2001). Towards a novel classification of human malignancies based on gene expression patterns. J. Pathol 195, 41–52. (Retrieved November 19th 2014): https://www.ncbi.nlm.nih.gov/pubmed/11568890
Allred, D.C., Bustamante, M.A., Daniel, C.O., Gaskill, H.V., Cruz, A.B. Jr. (1990). Immunocytochemical analysis of estrogen receptors in human breast carcinomas: evaluation of 130 cases and review of the literature regarding concordance with biochemical assay and clinical relevance. Arch Surg 125, 107–113. (Retrieved November 19th 2014): https://www.ncbi.nlm.nih.gov/pubmed/1688490
Allred, D.C., Harvey, J.M., Berardo, M., Clark, G.M. (1998). Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 11, 155-168. (Retrieved November 20th 2014): https://www.ncbi.nlm.nih.gov/pubmed/9504686
American Cancer Society: Cancer Facts and Figures 2014. Atlanta: American Cancer Society. (Retrieved 23rd October 2014): https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2014.html
American Joint Committee on Cancer (AJCC) Cancer Staging Manual, 7th edition, Edge, S.B., Byrd, D.R., Compton, C.C., et al (Eds), Springer, New York 2010.
Bijker, N., Meijnen, P., Peterse, J.L., et al. (2006). Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in-situ: Ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III Trial 10853—A study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. J Clin Oncol 24:3381-3387. (Retrieved November 6th 2014): https://www.ncbi.nlm.nih.gov/pubmed/16801628
Bradley, S.J., Weaver, D.W., Bowman, D.L. (1990). Alternatives in the surgical management of in situ breast cancer. A meta-analysis of outcome. Am J Surg 56(7):428. (Retrieved November 6th 2014): https://www.ncbi.nlm.nih.gov/pubmed/2164336
Brody, L.C. (2005). Treating cancer by targeting a weakness. N. Engl. J. Med. 353, 949–950. (Retrieved November 19th 2014): https://www.nejm.org/doi/full/10.1056/NEJMcibr052331
Bryan, B.B., Schnitt, S.J., Collins, L.C. (2006). Ductal carcinoma in situ with basal-like phenotype: a possible precursor to invasive basal-like breast cancer. Mod Pathol 19(5), 617-21. (Retrieved November 19th 2014): https://www.ncbi.nlm.nih.gov/pubmed/16528377
Carey, L., Winer, E., Viale, G., et al. (2010). Triple-negative breast cancer: disease entity or title of convenience? Nat Rev Clin Oncol 7, 683–692. (Retrieved November 21st 2014): https://www.ncbi.nlm.nih.gov/pubmed/20877296
Carlson, R.W., Moench, S.J., Hammond, M.E., et al. (2006). HER2 testing in breast cancer: NCCN task force report and recommendations. J Natl Compr Canc Netw 4(s3), S1–S22. https://www.ncbi.nlm.nih.gov/pubmed/1681373
Damera, A., Evans, A.J., Cornford, E. J. et al. (2003). Diagnosis of axillary nodal metastases by ultrasound‐guided core biopsy in primary operable breast cancer. Br J Cancer 89, 1310–1313. (Retrieved November 19th 2014): https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2394321/
Darby, S.C., McGale, P., Taylor, C.W., et al. (2005). Long-term mortality from heart disease and lung cancer after radiotherapy for early breast cancer: Prospective cohort study of about 300,000 women in US SEER cancer registries. Lancet Oncol 6:557-565. (Retrieved November 6th 2014): https://www.ncbi.nlm.nih.gov/pubmed/16054566
De Leeuw, W.J., Berx, G., Vos, C.B., Peterse, J.L., Van de Vijver, M.J., Litvinov, S., Van Roy, F., Cornelisse, C.J., Cleton-Jansen, A.M. (1997). Simultaneous loss of E-cadherin and catenins in invasive lobular breast cancer and lobular carcinoma in situ. J Pathol 183(4), 404. (Retrieved November 14th 2014): https://www.ncbi.nlm.nih.gov/pubmed/9496256
Dillon, M. F., Hill, A. D., Quinn, C. M.. et al . (2005). The accuracy of ultrasound, stereotactic, and clinical core biopsies in the diagnosis of breast cancer, with an analysis of false‐negative cases. Ann Surg 242, 701–707. (Retrieved November 20th 2014): https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1409862/
D’Orsi, C.J. (1995). Management of the breast specimen. Radiology 194(2), 297. (Retrieved November 20th 2014): https://pubs.rsna.org/doi/10.1148/radiology.194.2.7824700
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). (2005). Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: An overview of the randomised trials. Lancet 366, 2087-2106. (Retrieved November 13th 2014): https://www.sciencedirect.com/science/article/pii/S0140673605678877
Ellis, I.O., Humphreys, I.S., Michell, M., Pinder, S.E., Wells, C.A., Zakhour, H.D. (2004). Best Practice No 179. Guidelines for breast needle core biopsy handling and reporting in breast screening assessment. J Clin Pathol 57(9), 897–902. (Retrieved November 20th 2014): https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1770422/
Ellis, M.J., Suman, V.J., Hoog, J. et al. (2011). Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype – ACOSOG Z1031. J Clin Oncol 29, 2342–2349. (Retrieved November 21st 2014): https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3107749/
Estourgie, S.H., Nieweg, O.E., Kroon, B.B.R. (2004). Lymphatic drainage patterns from the breast. Ann Surg. 239(2), 232-7. (Retrieved November 5th 2014): https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1356216/
Fajardo, L. L., Pisano, E. D., Caudry, D.J. et al. (2004). Stereotactic and sonographic large‐core biopsy of nonpalpable breast lesions: results of the Radiologic Diagnostic Oncology Group V study. Acad Radiol 11, 293–308. (Retrieved November 19th 2014): https://www.ncbi.nlm.nih.gov/pubmed/15035520
Giordano, S.H., Cohen, D.S., Buzdar, A.U., Perkins, G., Hortobagyi, G.N. (2004). Breast carcinoma in men: a population-based study. Cancer. 101(1), 51. (Retrieved October 28th 2014): https://www.ncbi.nlm.nih.gov/pubmed/15221988
Goldhirsch, A., Wood, W.C., Coates, A.S. et al. (2011). Strategies for subtypes – dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 22, 1736–1747. (Retrieved November 21st 2014): https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3144634/
Goldstein, N.S., Hewitt, S.M., Taylor, C.R., et al. (2007). Recommendations for improved standardization of immunohistochemistry. Appl Immunohistochem Mol Morphol 15, 124–33. (Retrieved November 20th 2014): https://www.ncbi.nlm.nih.gov/pubmed/17525622
Goulding, H., Pinder, S., Cannon, P., et al. (1995). A new immunohistochemical antibody for the assessment of estrogen receptor status on routine formalin-fixed tissue samples. Hum Pathol 26, 291–4. (Retrieved November 20th 2014): https://www.ncbi.nlm.nih.gov/pubmed/7890280
Harvey, J.M., Clark, G.M., Osborne, C.K., Allred, D.C. (1999). Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 17, 1474–1481. (Retrieved November 19th 2014): https://www.ncbi.nlm.nih.gov/pubmed/10334533
Hughes, L.L., Wang, M., Page, D.L., Gray, R., Solin, L.J., Davidson, N.E., Lowen, M.A., Ingle, J.N., Recht, A., Wood, W.C. (2009). Local excision alone without irradiation for ductal carcinoma in situ of the breast: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol 27(32), 5319. (Retrieved November 6th 2014): https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2773217/
Lakhani, S., Ellis, I., Schnitt, S., et al. (2012). WHO Classification of Tumours of the Breast, 4th ed. Lyon, IARC Press. (Retrieved November 6th 2014): http://apps.who.int/bookorders/anglais/detart1.jsp?codlan=1&codcol=70&codcch=4004
Lerwill, M.F. (2004). Current practical applications of diagnostic immunohistochemistry in breast pathology. Am J Surg Pathol 28(8), 1076-91. (Retrieved November 19th 2014): https://www.ncbi.nlm.nih.gov/pubmed/15252316
Luporsi, E., André, F., Spyratos, F., et al. (2012). Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review. Breast Cancer Res Treat 132(3), 895-915. (Retrieved November 19th 2014): https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3332349/
McCormick, J.T., Keleher, A.J., Tikhomirov, V.B., Budway, R.J., Caushaj, P.F. (2004). Analysis of the use of specimen mammography in breast conservation therapy. Am J Surg 188(4), 433. (Retrieved November 19th 2014): https://www.ncbi.nlm.nih.gov/pubmed/15474443
Maluf, H.M., Swanson, P.E., Koerner, F.C. (2001). Solid low-grade in situ carcinoma of the breast: role of associated lesions and E-cadherin in differential diagnosis. Am J Surg Pathol 25, 237–44. (Retrieved November 19th 2014): https://www.ncbi.nlm.nih.gov/pubmed/11176073
Newman, E. L., Kahn, A., Diehl, K. M. et al. (2006). Does the method of biopsy affect the incidence of sentinel lymph node metastases? Breast J 12, 53–57. (Retrieved November 19th 2014): https://www.ncbi.nlm.nih.gov/pubmed/16409587
NHSBP. National Health Service Breast Program (NHSBP). (Retrieved 23rd October 2014): http://www.cancerscreening.nhs.uk/breastscreen/
Nielsen, T.O., Parker, J.S., Leung, S. et al. (2010). A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer. Clin Cancer Res 16, 5222–5232. (Retrieved November 21st 2014): https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2970720/
Parker, S. H., Burbank, F., Jackman, R. J. et al. (1994). Percutaneous large‐core breast biopsy: a multi‐institutional study. Radiology 193, 359–364. (Retrieved November 21st 2014): https://www.ncbi.nlm.nih.gov/pubmed/7972743
Perou, C.M., Jeffrey, S.S., van de Rijn, M., Rees, C.A. et al. (1999). Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. Proc. Natl. Acad. Sci. USA 96, 9212–9217. (Retrieved November 19th 2014): https://www.ncbi.nlm.nih.gov/pubmed/10430922
Petitjean, A., Mathe, E., Kato, S., Ishioka, C., Tavtigian, S.V., Hainaut, P., Olivier, M. (2007). Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat 28(6), 622-9. (Retrieved November 19th 2014): https://www.ncbi.nlm.nih.gov/pubmed/17311302
Rosen PP. Rosen’s Breast Pathology. 2nd edn. Philadelphia: Lippincott Williams & Wilkins, 2001.
Ross, J.S., Symmans, W.F., Pusztai, L., et al. (2007). Standardizing slide-based assays in breast cancer: hormone receptors, HER2, and sentinel lymph nodes. Clin Cancer Res 13, 2831–5. (Retrieved November 20th 2014): http://clincancerres.aacrjournals.org/content/13/10/2831.abstract?ijkey=7b4540ef7b3ad0ebc67b5874f63a885a555c60df&keytype2=tf_ipsecsha
Rouzier, R., Perou, C.M., Symmans, W.F., et al. (2005). Breast cancer molecular sub- types respond differently to preoperative chemotherapy. Clin Cancer Res 11, 5678–5685. (Retrieved November 19th 2014): https://www.ncbi.nlm.nih.gov/pubmed/16115903
Russo, J., Ao, X., Grill, C., Russo, I.H. (1999). Pattern of distribution of cells positive for estrogen receptor alpha and progesterone receptor in relation to proliferating cells in the mammary gland. Breast Cancer Res Treat. 53(3), 217. (Retrieved November 5th 2014): https://www.ncbi.nlm.nih.gov/pubmed?term=10369068
Schnitt, S.J. (2006). Estrogen receptor testing of breast cancer in current clinical practice: what’s the question? J Clin Oncol 24, 1797–9. (Retrieved November 20th 2014): https://www.ncbi.nlm.nih.gov/pubmed/16567766
Sinn, H.P., Kreipe, H. (2013). A Brief Overview of the WHO Classification of Breast Tumors, 4th Edition, Focusing on Issues and Updates from the 3rd Edition. Breast Care 8(2):149-54. doi: 10.1159/000350774. (Retrieved November 5th 2014): https://www.ncbi.nlm.nih.gov/pubmed/24415964
Simpson, J.L., Page, D.L. (1996). The role of pathology in premalignancy and as a guide for treatment and prognosis in breast cancer. Semin Oncol. 23(4), 428-35. (Retrieved November 6th 2014): https://www.ncbi.nlm.nih.gov/pubmed/8757269
Slamon, D.J., Clark, G.M., Wong, S.G., Levin, W.J., Ullrich, A., McGuire, W.L. (1987). Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235, 177–182. (Retrieved November 19th 2014): https://www.ncbi.nlm.nih.gov/pubmed/3798106
Solin, L.J., Fourquet, A., Vicini, F.A. et al. (2005). Long-term outcome after breast-conservation treatment with radiation for mammographically detected ductal carcinoma in situ of the breast. Cancer 103(6), 1137. (Retrieved November 13th 2014): https://www.ncbi.nlm.nih.gov/pubmed/15674853
Sotiriou C, Pusztai L. (2009). Gene-expression signatures in breast cancer. N. Engl. J. Med. 360, 790–800. (Retrieved November 19th 2014): https://www.ncbi.nlm.nih.gov/pubmed/19228622
Staley, H., McCallum, I., Bruce, J. (2012). Postoperative tamoxifen for ductal carcinoma in situ. Cochrane Database Syst Rev 10, CD007847. (Retrieved November 6th 2014): https://www.ncbi.nlm.nih.gov/pubmed/23076938
Tallent, A. (2013). ASCO and the CAP Release Updated Guideline on HER2 Testing in Breast Cancer. Press Release, October 7, 2013. (Retrieved November 14th 2014): https://www.asco.org/advocacy-policy/asco-in-action/twenty-oncology-practices-achieve-qopi-certification-Q2-2019
Tse, G.M., Tan, P.H., Lui, P.C., et al. (2007). The role of immunohistochemistry for smooth muscle actin, p63, CD10 and CK14 in the differential diagnosis of papillary lesions of the breast. J Clin Pathol 2007;60:315–20. (Retrieved November 20th 2014): https://www.ncbi.nlm.nih.gov/pubmed/16698948
Viale, G. (2012). The current status of breast cancer classification. Annals Oncology 23(S10), 207-210. (Retrieved November 20th 2014): https://www.ncbi.nlm.nih.gov/pubmed/22987963
Walker, R.A. (2008). Immunohistochemical markers as predictive tools for breast cancer. J Clin. Pathol. 61, 689–696. (Retrieved November 20th 2014): https://www.ncbi.nlm.nih.gov/pubmed/18037665
Walker, R.A., Hanby, A., Pinder, S.E., Thomas, J., Ellis, I.O. National Coordinating Committee for Breast Pathology Research Subgroup. (2012). Current issues in diagnostic breast pathology. J Clin Pathol 65(9), 771-85. (Retrieved November 20th 2014): https://www.ncbi.nlm.nih.gov/pubmed/22813732
Weslowski, R., Ramaswamy, B. (2011). Gene Expression Profiling: Changing Face of Breast Cancer Classification and Management. 15, 105-115. (Retrieved November 20th 2014): https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3772713/
Wolff, A.C., Hammond, E.H., Schwartz, J.N., et al. (2007). American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 131, 18–43. (Retrieved November 20th 2014): https://www.ncbi.nlm.nih.gov/pubmed/19548375
Wolff, A.C., Hammond, E., Hicks, D.G. et al. (2013). Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update. J Clin Oncol 31(31), 3997-4013. (Retrieved November 12th 2014): http://www.asco.org/quality-guidelines/recommendations-human-epidermal-growth-factor-receptor-2-testing-breast-cancer and http://jco.ascopubs.org/content/31/31/3997.full
Yeh, I-T., Mies, C. (2008). Application of Immunohistochemistry to Breast Lesions. Arch Pathol Lab Med 132, 349-358. (Retrieved November 20th 2014): https://www.ncbi.nlm.nih.gov/pubmed/18318578
